Cara Therapeutics

📍 Stamford, United States🗓 Founded 2004👥 102 employees💰 Last funded Aug 2023
Biotechnology Research🌐 caratherapeutics.com
Website LinkedIn
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2004
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Cara Therapeutics?
Cara Therapeutics has 1 investors on record on gritt.io.
When did Cara Therapeutics last raise funding?
The most recent investment in Cara Therapeutics recorded on gritt.io was in August 2023.
When was Cara Therapeutics founded?
Cara Therapeutics was founded in 2004.
What industry is Cara Therapeutics in?
Cara Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Cara Therapeutics based?
Cara Therapeutics is headquartered in Stamford, United States.